BMI Seminar // Li-Huei Tsai - Enhancing Gamma Oscillations in Alzheimer's Disease: mechanism and pilot study in humans
Exceptionally on Friday at 11 AM!
Rhythmic neural activity in the gamma range (30-80 Hz) is modulated during various aspects of cognitive function and is disrupted in several neurological conditions, including Alzheimer's disease (AD). We developed an approach which we term Gamma ENtrainment Using Sensory stimuli (GENUS), using patterned light and sound stimulation at 40 Hz in AD model mice to evaluate the effects of boosting gamma oscillations. We showed GENUS augmented gamma power in multiple brain regions. Moreover, daily application markedly reduced amyloid and tau pathology, attenuated degeneration of neurons and synapses, and improved cognitive function in multiple AD mouse models. In addition, GENUS induced morphological and gene expression changes of various cell types, including microglia and enhanced vasodilation. GENUS also enhanced glial-mediated and lymphatic-like brain waste clearance, known as glymphatic clearance, in a VIP interneuron dependent manner. Based on these studies, we hypothesized that gamma entrainment with light and sound can be used as a disease-modifying therapeutic for AD. We conducted a placebo-controlled, randomized control trial (n = 15) in subjects with probable mild AD to use our light and sound device at home for one hour daily (NCT 04042922). We report interim results after 3 months of daily 40Hz stimulation. Gamma frequency light and sound stimulation can be used safely daily for 3 months and prevents AD-related degeneration. Induced entrainment using sensory stimulation at 40Hz shows promise as a novel disease modifying therapeutic for Alzheimer’s dementia.
Rhythmic neural activity in the gamma range (30-80 Hz) is modulated during various aspects of cognitive function and is disrupted in several neurological conditions, including Alzheimer's disease (AD). We developed an approach which we term Gamma ENtrainment Using Sensory stimuli (GENUS), using patterned light and sound stimulation at 40 Hz in AD model mice to evaluate the effects of boosting gamma oscillations. We showed GENUS augmented gamma power in multiple brain regions. Moreover, daily application markedly reduced amyloid and tau pathology, attenuated degeneration of neurons and synapses, and improved cognitive function in multiple AD mouse models. In addition, GENUS induced morphological and gene expression changes of various cell types, including microglia and enhanced vasodilation. GENUS also enhanced glial-mediated and lymphatic-like brain waste clearance, known as glymphatic clearance, in a VIP interneuron dependent manner. Based on these studies, we hypothesized that gamma entrainment with light and sound can be used as a disease-modifying therapeutic for AD. We conducted a placebo-controlled, randomized control trial (n = 15) in subjects with probable mild AD to use our light and sound device at home for one hour daily (NCT 04042922). We report interim results after 3 months of daily 40Hz stimulation. Gamma frequency light and sound stimulation can be used safely daily for 3 months and prevents AD-related degeneration. Induced entrainment using sensory stimulation at 40Hz shows promise as a novel disease modifying therapeutic for Alzheimer’s dementia.
Links
Practical information
- Informed public
- Free
Organizer
- SV BMI Host : Johannes Gräff